Navigation Links
Researchers led by Penn vet uncover the delicate protein balance behind the immune system response
Date:12/10/2007

PHILADELPHIA - A team of researchers from the University of Pennsylvania School of Veterinary Medicine has identified the protein interactions involved in the immune system process that fights infection yet, in certain inflammatory diseases, runs amok and attacks friendly tissue.

The Penn team, led by Christopher Hunter, chair of the Department of Pathobiology at Penn Vet, has identified the pathways that lead to the production of the signaling protein, or cytokine, Interleukin 10 (IL-10) which plays an important role in regulating the balance between the protective white blood, or T, cell response and one that is pathological and out of control.

While IL-10 has long been recognized as a major anti-inflammatory factor, the events that lead to its production have been poorly understood. According to the researchers findings, messenger proteins Interleukin 27, or a combination of Interleukin 6 and another type of messenger molecule called transforming growth factor beta, induce production of IL-10. These results suggest that modulating these messenger molecules could increase IL-10 concentrations that temper overactive immune responses.

This information sheds new light on the immune-system response and may provide directed means to intervene in severe autoimmune diseases such as colitis, multiple sclerosis and arthritis.

The deeper we delve into the role of cytokines in the immune system response, the more we realize that they are part of an elaborately balanced system kept in check by the conflicting regulatory functions of the cytokines themselves, Hunter said. When combined with the work from our colleagues at Schering Plough, Harvard and Jefferson University, these studies provide new insights into the pathways that can be used to temper autoimmune inflammation.

Although there are many sources of IL-10 in the body, the details of how it is synthesized were poorly understood. Hunters team determined that the process begins with cytokines IL-27 and IL-6 inducing production Th1 , Th2 and Th17 T cells and concludes that cytokines like IL-27 can promote the ability of these cells to produce IL-10. The effect was dependent on the transcription factors STAT1 and STAT3 for IL-27 and on STAT3 for IL-6.

Researchers tested this hypothesis by removing the IL-27 receptor from genetically engineered mice. Once infected with disease, the mice were unable to generate T cells producing IL-10.

In prior studies, Penn researchers learned that Interluekin-27 was involved in the immune-system response by limiting the duration and intensity of white blood activation, an "off switch" to the cascade of messenger proteins that serve to further activate the immune system. Prior to their research, the general assumption among scientists was that IL-27 promoted inflammation.


'/>"/>

Contact: Jordan Reese
jreese@upenn.edu
215-573-6604
University of Pennsylvania
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: